The IASLC 2021 World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians, and professionals in the field of lung cancer and thoracic oncology.
Opens September 1, 2021, 15:00 MDT
Ends September 30, 2021, 15:00 MDT
Meet our lineup of exhibitors attending WCLC 2021. Click on their logo to learn more about them.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Please note that Amgen’s approved corporate descriptions are subject to periodic updates. To obtain the latest version of this corporate description, please visit the Communication Materials and Tools page on MyAmgen.
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that unequivocally work in early clinical development and will matter to patients. To learn more about Lilly's commitment to people with cancer, please visit LillyLoxoOncologyPipeline.com.
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using innovative technology platforms. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme is the specialty care business of Sanofi, focusing on difficult to treat conditions.
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
At Merck, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry.
Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and hematologic disorders.
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are providing new hope for patients, by taking cancer on.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.
We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges.
For more information:www.takedaoncology.com.
With the Monarch™ Platform, Auris Health helps physicians diagnose small peripheral nodules by leveraging the precision of a robotically controlled bronchoscope
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer currently includes six marketed products. Several other compounds are in various stages of clinical development, with the focus on potential first-in-class approaches across the areas of precision molecular oncology, targeted alpha therapies, and immuno-oncology. An Oncology Strategic Business Unit within the Pharmaceuticals Division of Bayer was established in 2017 to support the accelerated development of new treatment options. The company has also established a broad cooperative research network with healthcare professionals, academic research centers, other pharmaceutical companies and innovative biotech organizations worldwide. Together with these partners, we are fostering an open exchange of ideas to expand Bayer's vision of treatment for cancer patients.
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.
To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). For additional information, please visit www.coherus.com.
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, nd DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care. For more information, visit https://www.emdserono.com/us-en.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smart solutions providing the clarity to take life-changing action, earlier.
Oncotype MAP™ Pan-Cancer Tissue Test
The Oncotype MAP™ Pan-Cancer Tissue Test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days* to guide timely treatment decisions, usually before the next follow up visit.
*Data on file. Turnaround time is based on qualified sample receipt.
Our mission is to develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing two novel therapies for people living with cancer. COSELA™ (trilaciclib) is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices.
Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature. We are experts in applying adult learning theory and principles to our programs and, more importantly, understand the nuances of our specialty audiences. We design programs for physicians, nurses, pharmacists and other healthcare practitioners and have a deep understanding of how to educate both specialty audiences and general practitioners.
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease detection and recurrence monitoring. Signatera's tumor-informed test has been validated in multiple solid tumors including melanoma for immunotherapy response monitoring. Dive deeper at www.natera.com/oncology
NeoGenomics specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to diagnose and treat cancer with >600 tests available in-house including extensive molecular profiling in myeloid disorders and leukemias, cfDNA/RNA assays for biopsy-free evaluation of hematologic cancers, and >20 HemeFISH™ panels. Our Pharma Services Division serves pharmaceutical clients in clinical trials and drug development from biomarker discovery through CDx validation and commercialization. Collaborations welcome.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development of its innovative therapy, Tumor Treating Fields (TTFields). Novocure has ongoing clinical trials investigating TTFields targeting specific lung, pancreatic, ovarian, hepatic, and gastric cancers, brain metastasis, and glioblastoma.
The information provided here is intended as an educational resource for healthcare professionals and researchers practicing in the United States. It may include information about products or uses that have not been approved by the U.S. Food and Drug Administration. If you are not a U.S. healthcare professional or researcher, please visit Novocure.com.
Oncocyte is a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer.
Oncocyte’s DetermaTM product platform delivers critical information throughout the patient journey.
DetermaRx is a genomic test performed on formalin fixed paraffin embedded tissue from patients that have been recently resected for early stage non-squamous, non-small cell lung cancer. The results stratify patients into low, intermediate or high risk of recurrence, and physicians can utilize those results to tailor treatment and surveillance strategies. The test has been approved by Medicare for patients with Stage I-IIA non-squamous NSCLC.
DetermaIO is a potentially transformative immunotherapy diagnostic that comprehensively measures immune response in a tumor specimen. In published studies, DetermaIO outperformed both PD-L1 and Tumor Mutational Burden in identifying responders to immune checkpoint inhibitors.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. The Clinical Sequencing Division is enabling precision oncology research with easily implementable next-generation sequencing (NGS) Oncomine Solutions, powered by the Ion Torrent Technology. The latest development, the Genexus NGS System, allows labs to deliver NGS results in less than 24 hours, at the same time as single-gene methods like immunohistochemistry (IHC). NGS is now more accessible than ever.
Meet our lineup of other sponsors for WCLC 2021. Click on their logo to learn more about them.
Clinical Care Options (CCO) is a global education leader focusing on innovative educational activities for healthcare professionals, across multiple therapeutic areas.
The mission of CCO is to improve clinical care and patient health through the delivery of clinically relevant, evidence-based educational activities.
Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME.
Mirati Therapeutics Inc., is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
PeerView Institute for Medical Education, Inc. (PVI) is a leader in the development and dissemination of accredited continuing educational programming for the global healthcare professional community. Since 2004, PeerView has created interactive online activities, organized live in-person and virtual symposia in conjunction with national and international congresses, and implemented quality improvement projects and workshops held locally and regionally in collaboration with practices, institutions, and professional societies and associations. Our expansive network of media platforms and distribution channels engages one of the world’s largest clinician networks, bringing education to busy professionals when, where, and how they learn best.
PVI is jointly accredited by the ACCME, ACPE, and ANCC to provide interprofessional continuing education planned by and for the healthcare team enabling physicians, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals to earn free CME/MOC/CE credit toward maintenance of their licensure and/or certification. PVI maintains strict adherence to the Standards for Integrity and Independence set forth by the ACCME as well as to PhRMA, AMA, and OIG guidelines.
Research To Practice (RTP) is a medical education company based in Miami, Florida specializing in physician and allied health professional education focused exclusively on oncology and hematology. Founded and led by medical oncologist, Neil Love, MD, RTP has provided meaningful, relevant and unbiased educational perspectives for more than 30 years to meet the needs of oncology clinicians and positively impact the care of patients with cancer.
All of RTP’s CME activities help bridge the gap between research and patient care and assist practitioners in clinical decision-making by providing ongoing access to the opinions and perspectives of internationally recognized cancer clinical investigators. Using a variety of distinct formats and approaches including audio interviews, case-based discussions, Patterns of Care studies, web-based video, patient perspectives projects and others, RTP creates truly unique enduring and live CME, NCPD and other accredited activities and series that are highly respected and used by the vast majority of cancer clinicians in the United States. To learn more about Research To Practice and our complimentary educational activities, please visit: www.ResearchToPractice.com
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
International Association for the Study of Lung Cancer (IASLC)
CorporateRelations at iaslc.org
Phone: +1 720 598 1951
Fax: +1 720 325 2848
Keep up to date with Conference News & Alerts.